Literature DB >> 16436749

In vitro activity of DX-619, a novel des-fluoro(6) quinolone, against a panel of Streptococcus pneumoniae mutants with characterized resistance mechanisms.

Paul A Wickman1, Ellen Smith Moland, Jennifer A Black, Kenneth S Thomson.   

Abstract

The in vitro activities of DX-619 and four other quinolones were compared against Streptococcus pneumoniae mutants that contained a variety of alterations within the quinolone resistance-determining regions. DX-619 was the most potent quinolone and was least affected by the mutations.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16436749      PMCID： PMC1366926          DOI： 10.1128/AAC.50.2.796-798.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  J Liñares; A G de la Campa; R Pallares
Journal:  N Engl J Med       Date:  1999-11-11       Impact factor: 91.245

2.  In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone.

Authors:  Katsuko Fujikawa; Megumi Chiba; Mayumi Tanaka; Kenichi Sato
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

3.  The effect of reserpine, an inhibitor of multi-drug efflux pumps, on the in-vitro susceptibilities of fluoroquinolone-resistant strains of Streptococcus pneumoniae to norfloxacin.

Authors:  N P Brenwald; M J Gill; R Wise
Journal:  J Antimicrob Chemother       Date:  1997-09       Impact factor: 5.790

4.  Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland.

Authors:  C E Goldsmith; J E Moore; P G Murphy; J E Ambler
Journal:  J Antimicrob Chemother       Date:  1998-03       Impact factor: 5.790

5.  Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.

Authors:  P L Ho; R W Yung; D N Tsang; T L Que; M Ho; W H Seto; T K Ng; W C Yam; W W Ng
Journal:  J Antimicrob Chemother       Date:  2001-11       Impact factor: 5.790

6.  Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.

Authors:  D J Bast; D E Low; C L Duncan; L Kilburn; L A Mandell; R J Davidson; J C de Azavedo
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

7.  Incidence, epidemiology, and characteristics of quinolone-nonsusceptible Streptococcus pneumoniae in Croatia.

Authors:  Glenn A Pankuch; Bülent Bozdogan; Kensuke Nagai; Arjana Tambić-Andrasević; Slavko Schoenwald; Tera Tambić; Smilja Kalenić; Sanja Plesko; Nastja K Tepes; Zdenka Kotarski; Marina Payerl-Pal; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.

Authors:  N P Brenwald; M J Gill; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

9.  Quinolone resistance among pneumococci: therapeutic and diagnostic implications.

Authors:  Donald E Low
Journal:  Clin Infect Dis       Date:  2004-05-15       Impact factor: 9.079

10.  Primary targets of fluoroquinolones in Streptococcus pneumoniae.

Authors:  H Fukuda; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191
View more
  3 in total

1.  Intracellular penetration and activity of DX-619 in human polymorphonuclear leukocytes.

Authors:  Isabel García; Sofía Ballesta; Concepción Murillo; Evelio J Perea; Alvaro Pascual
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Lack of effect of DX-619, a novel des-fluoro(6)-quinolone, on glomerular filtration rate measured by serum clearance of cold iohexol.

Authors:  Nenad Sarapa; Prachi Wickremasingha; Nanxiang Ge; Richard Weitzman; Merynda Fuellhart; Cindy Yen; Julia Lloyd-Parks
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

Review 3.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.